Facebook Pixel Code
Banner image
iPOG Network

Research Gaps Identified

  • Emetogenicity Classification of Chemotherapy
    • Emetogenicity of chemotherapy and chemotherapy combinations where scant direct pediatric evidence exists (e.g. dacarbazine, ifosfamide, intermediate dose methotrexate)
  • Prevention of Acute Chemotherapy-induced Nausea and Vomiting
    • Optimal dose of dexamethasone for use in children receiving highly emetogenic chemotherapy 
    • Safe and effective alternatives to dexamethasone
    • Safe and effective alternatives to aprepitant
  • Prevention and Treatment of Anticipatory Chemotherapy-induced Nausea and Vomiting
    • Optimal dose of lorazepam
  • Primary Antifungal Prophylaxis
  • Management of Fever and Neutropenia
  • Prevention of oral and oropharyngeal mucositis
  • Treatment of Breakthrough Chemotherapy-induced Nausea and Vomiting
    • Efficacy of CINV prophylaxis escalation
  • Prevention of Refractory Chemotherapy-induced Nausea and Vomiting
    • Optimal palonosetron dose in children receiving multiple day chemotherapy